United Bank Increases Stock Position in GSK plc (NYSE:GSK)

United Bank increased its position in shares of GSK plc (NYSE:GSK) by 22.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,449 shares of the pharmaceutical company’s stock after purchasing an additional 5,664 shares during the quarter. United Bank’s holdings in GSK were worth $1,064,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in shares of GSK by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,603 shares of the pharmaceutical company’s stock worth $4,971,000 after buying an additional 14,687 shares during the last quarter. Larson Financial Group LLC lifted its holdings in GSK by 527.4% during the third quarter. Larson Financial Group LLC now owns 1,807 shares of the pharmaceutical company’s stock worth $74,000 after acquiring an additional 1,519 shares during the period. Townsquare Capital LLC lifted its holdings in GSK by 7.8% during the third quarter. Townsquare Capital LLC now owns 98,367 shares of the pharmaceutical company’s stock worth $4,021,000 after acquiring an additional 7,151 shares during the period. CreativeOne Wealth LLC purchased a new position in GSK in the third quarter worth $213,000. Finally, Fiduciary Trust Co grew its stake in GSK by 2.8% in the 3rd quarter. Fiduciary Trust Co now owns 17,638 shares of the pharmaceutical company’s stock valued at $721,000 after purchasing an additional 486 shares during the period. 15.74% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of research analyst reports. Morgan Stanley initiated coverage on shares of GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Up 0.6 %

GSK opened at $38.74 on Friday. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93. The company has a market cap of $80.19 billion, a PE ratio of 24.37, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a 50 day moving average of $37.22 and a 200 day moving average of $36.74.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, sell-side analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.06%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio is presently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.